SANTHERA ENROLLS LAST PATIENT IN RHODOS STUDY. (cover story)

The article reports on the completion of patient recruitment for the six-month Rescue of Hereditary Optic Disease Outpatient Study (RHODOS) of Santhera Pharmaceuticals in 2009. The study will examine the effects of its Catena drug on patients with Leber's hereditary optic neuropathy (LHON). The trials to be done in Munich, Germany, Newcastle, England and Montreal, Quebec is considered the first to test the efficacy of Catena against placebo, and the rationale that Catena may delay vision loss in LHON.